Researchers found that peripheral injections of etanercept normalize the depressive effects of repeated steroid administration in an animal model.
There is a strong connection between the immune system and the brain in the context of depression. Chronic stress induces an inflammatory response in the body, which in the central nervous system includes an increase in pro-inflammatory cytokines. A recent study investigated whether peripheral injections of the anti—tumor necrosis factor (anti-TNF) inhibitor etanercept can help treat depression.
The study was conducted in an animal model comprising 24 male Long-Evans rats. The rats were randomly assigned to one of the following treatment groups:
All steroid and vehicle injections were administered once a day subcutaneously for 21 consecutive days. Etanercept and saline injections were given subcutaneously twice per week for 21 days. In addition, behavioral tests were conducted in the form of a forced swim test, an object-recognition memory test, and an object-in-place paradigm test.
The results of the experiment show that prolonged exposure to steroids produces a cluster of effects characterized by increased immobility in the swim test, impaired spatial memory on the object location and object-in-place tests, and reduced hippocampal neurogenesis. However, semi-weekly etanercept giving concurrently with steroids prevented all of these effects, which suggested that anti-TNF drugs could have a role in treating depression.
A particularly noteworthy finding of the study was that peripheral administration of etanercept restored steroid-induced deficits in hippocampal neurogenesis. However, the role of hippocampal neurogenesis in depression is a controversial issue, as the removal of hippocampal neurogenesis does not always induce depression-like behavior, and antidepressant effects can be seen without increases in neurogenesis.
The study also found that peripheral injections of etanercept normalize steroid-induced deficits in hippocampal reelin (a glycoprotein) expression. This idea comes from previous observations that reelin-overexpressing mice have increased neurogenesis, and that exogenous reelin can recover cognitive deficits in mouse models of both Angelman syndrome and Alzheimer disease. These observations correlate with the findings of this study that etanercept restores both object-location and object-in-place memory.
The researchers found that peripheral injections of etanercept normalize the depressive effects of repeated steroid administration. These results add to previous studies that suggested inflammatory events are a critical component of the pathogenesis of depression, and that there could be a key link between the immune system and the brain.
Reference
Brymer K, Fenton E, Kalychuk L, Caruncho H. Peripheral etanercept administration normalizes behavior, hippocampal neurogenesis, and hippocampal reelin and GABAA receptor expression in a preclinical model of depression [published online February 20, 2018]. Front Pharmacol. doi:10.3389/fphar.2018.00121.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.